Pages that link to "Q54395375"

The following pages link to Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. (Q54395375):

Displaying 15 items.

• Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics (Q37718173) (← links)
• Progress toward Gene Therapy for Duchenne Muscular Dystrophy (Q39246797) (← links)
• The role of RNA alternative splicing in regulating cancer metabolism. (Q39253959) (← links)
• Tween 85-Modified Low Molecular Weight PEI Enhances Exon-Skipping of Antisense Morpholino Oligomer In Vitro and in mdx Mice. (Q47147153) (← links)
• Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. (Q47153293) (← links)
• Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy (Q47607001) (← links)
• Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. (Q48263612) (← links)
• PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment (Q48620752) (← links)
• Synthesis of Azanucleosides by Anodic Oxidation in a Lithium Perchlorate-Nitroalkane Medium and Diversification at the 4'-Nitrogen Position (Q50681269) (← links)
• Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy. (Q51029797) (← links)
• Treating pediatric neuromuscular disorders: The future is now. (Q52756417) (← links)
• Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy (Q56986031) (← links)
• Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle (Q64241383) (← links)
• Advances in oligonucleotide drug delivery (Q98386176) (← links)
• Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway (Q99557476) (← links)